![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 301, Issue 1, 258-265, April 2002
Release During Acute Lung Injury in Mice: The Role of the Balance
Between Tumor Necrosis Factor-
and Interleukin-10
Institut National de la Santé et de la Recherche Medicale U
456, Faculté des Sciences Pharmaceutiques et Biologiques,
Université de Rennes 1, Rennes, France (M.C., N.G., J.L., S.M.,
E.B., V.L.); and Departamento de Fisiologia e Farmacodinâmica,
Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro, Brazil (P.M.R.e.S.,
M.A.M.)
Matrix metalloproteinases (MMPs) and transforming growth factor
(TGF)-
are involved in airway remodeling associated with the
inflammatory process. In this study, we investigated the effect of RP
73-401 (piclamilast), a selective phosphodiesterase-4 inhibitor, on MMP-9 activity and TGF-
production in two murine models of acute
inflammation. In the first model, the lipopolysaccharide (LPS)-induced
increase in neutrophils, MMP-9 activity, and tumor necrosis factor
(TNF)-
and TGF-
release in bronchoalveolar lavage (BAL)
was significantly reduced by RP 73-401 pretreatment. In contrast, the
BAL interleukin (IL)-10 level was decreased by LPS but restored by RP
73-401. IL-10 administration in LPS-exposed mice elicited a significant
reduction in BAL neutrophilia, MMP-9 activity, and TNF-
release but
not in TGF-
production. In the second model, RP 73-401 inhibited BAL
neutrophils but not MMP-9 activity and TGF-
production that were
induced by intranasal TNF-
. We demonstrated that RP 73-401 might
modulate the expression of airway remodeling-associated mediators such
as MMP-9 and TGF-
and that this effect seemed to be at least
partially mediated by the balance between TNF-
and IL-10.
This article has been cited by other articles:
![]() |
L. De Franceschi, O. S. Platt, G. Malpeli, A. Janin, A. Scarpa, C. Leboeuf, Y. Beuzard, E. Payen, and C. Brugnara Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice FASEB J, June 1, 2008; 22(6): 1849 - 1860. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. McCluskie, U. Klein, C. Linnevers, Y.-h. Ji, A. Yang, C. Husfeld, and G. R. Thomas Phosphodiesterase Type 4 Inhibitors Cause Proinflammatory Effects in Vivo J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 468 - 476. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Leclerc, V. Lagente, J-M. Planquois, C. Berthelier, M. Artola, T. Eichholtz, C. P. Bertrand, and F. Schmidlin Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice Eur. Respir. J., June 1, 2006; 27(6): 1102 - 1109. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Videla, J. Vilaseca, C. Medina, M. Mourelle, F. Guarner, A. Salas, and J.-R. Malagelada Selective Inhibition of Phosphodiesterase-4 Ameliorates Chronic Colitis and Prevents Intestinal Fibrosis J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 940 - 945. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Oger, C. Mehats, E. Dallot, D. Cabrol, and M.-J. Leroy Evidence for a Role of Phosphodiesterase 4 in Lipopolysaccharide-Stimulated Prostaglandin E2 Production and Matrix Metalloproteinase-9 Activity in Human Amniochorionic Membranes J. Immunol., June 15, 2005; 174(12): 8082 - 8089. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ariga, B. Neitzert, S. Nakae, G. Mottin, C. Bertrand, M. P. Pruniaux, S.-L. C. Jin, and M. Conti Nonredundant Function of Phosphodiesterases 4D and 4B in Neutrophil Recruitment to the Site of Inflammation J. Immunol., December 15, 2004; 173(12): 7531 - 7538. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.R.M. Rocco, D.P. Momesso, R.C. Figueira, H.C. Ferreira, R.A. Cadete, A. Legora-Machado, V.L.G. Koatz, L.M. Lima, E.J. Barreiro, and W.A. Zin Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury Eur. Respir. J., July 1, 2003; 22(1): 20 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Atkinson and R. M. Senior Matrix Metalloproteinase-9 in Lung Remodeling Am. J. Respir. Cell Mol. Biol., January 1, 2003; 28(1): 12 - 24. [Abstract] [Full Text] [PDF] |
||||